SECOND AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENTOncosignature Companion Diagnostic Agreement • March 28th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT (the “Second Amendment”) is made and entered into as of June 19, 2023 (the “Second Amendment Effective Date”) by and between:
First Amendment to ONCOSIGNATURE COMPANION DIAGNOSTIC AgreementOncosignature Companion Diagnostic Agreement • March 28th, 2023 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Oncosignature Companion Diagnostic Agreement (the “First Amendment”) is made and entered into as of December 21, 2022 (the “First Amendment Effective Date”) by and between:
SECOND AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENTOncosignature Companion Diagnostic Agreement • August 11th, 2023 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
This Second Amendment to Oncosignature Companion Diagnostic Agreement (the “Second Amendment”) is made and entered into as of June 19, 2023 (the “Second Amendment Effective Date”) by and between:
THIRD AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENTOncosignature Companion Diagnostic Agreement • March 28th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
This Third Amendment to Oncosignature Companion Diagnostic Agreement (the “Third Amendment”) is made and entered into as of December 4, 2023 (the “Third Amendment Effective Date”) by and between:
FOURTH AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENTOncosignature Companion Diagnostic Agreement • November 13th, 2024 • Acrivon Therapeutics, Inc. • Pharmaceutical preparations
This FOURTH AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT (this “Fourth Amendment”) is effective as of September 30, 2024 (the “Fourth Amendment Effective Date”) by and between:
